J&J wins CE mark for stroke tech; ItriCon eyes layoffs;

 @FierceMedDev: MC10 pushes wearable sensors with Medtronic co-sign. News | Follow @FierceMedDev

 @DamianFierce: ICYMI: Startup NeuroTronik raised $13.1M to develop a neuromodulation solution for heart failure. News | Follow @DamianFierce

 @MarkHFierce: Nearly $10M in new financing will help Veniti gain CE marking for vein treatment devices. Report | Follow @MarkHFierce

> Codman Neuro, a division of Johnson & Johnson ($JNJ), won a CE marking for Revive SE, a next-generation self-expanding clot removal device to treat acute ischemic stroke. Item

> Industry insiders are generally optimistic about the Myriad Genetics ($MYGN) ruling that determined no company can patent human genes isolated from the bloodstream. Story

> SV Bio won CLIA certification for its California computational laboratory, which performs gene sequencing-based diagnostics tests. News

> CryoLife bought Hemosphere last month and now the company's HerRO graft system to treat end-stage renal disease hemodialysis patients has obtained a CE mark. Item

> IntriCon, which makes hearing aids and various medical devices, said it will lay off 35 people out of its 569-employee workforce. Item

> Surgical robots are growing in popularity, The Pittsburgh Business Times reports. Item (sub. req.)

Biotech News

 @FierceBiotech: From FierceBiomarkers.com : Brain scan may provide biomarker guideposts to ideal depression treatment. Article | Follow @FierceBiotech

 @JohnCFierce: Look for early competition on hep C: Gilead 1, AbbVie in photo finish 2; BMS 3. As ranked by BloombergReport | Follow @JohnCFierce

 @RyanMFierce: AbbVie: We can beat Gilead in blockbuster hep C race. Report | Follow @RyanMFierce

 @EmilyMFierce: This week's roundup of hirings and new appointments in biopharma is here. | Follow @EmilyMFierce

> AbbVie: We can beat Gilead in blockbuster hep C race. Story

> Elan shares jump on news of sale process for the biotech. Report

> Eli Lilly racks up another Alzheimer's failure after BACE drug sparks safety fears. Article

Pharma News

 @FiercePharma: Come join our new LinkedIn group to connect with others in the industry and read, share and discuss the latest news. Join the group | Follow @FiercePharma

 @EricPFierce: FDA approves Amgen's Xgeva for bone tumor. It is a small market for a key drug that is not yet a blockbuster. Press release | Follow @EricPFierce

 @CarlyHFierce: Gleevec patent battle between Novartis and Sun Pharma moving to the U.S. Yesterday's story | Follow @CarlyHFierce

> AbbVie says it could beat Gilead to huge market for hep C drugs. More

> Wockhardt gets kicked in the gut again. Report

> Pfizer's potential stars Eliquis, Xeljanz see sluggish sales. Story

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.